$COGT
Cogent Biosciences, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020039357 Filed on August 11, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $530.0K $3.138M
YoY Change -83.11% 88.36%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.800M $3.060M
YoY Change -8.5% 54.55%
% of Gross Profit
Research & Development $5.129M $10.62M
YoY Change -51.69% 16.34%
% of Gross Profit
Depreciation & Amortization $280.0K $330.0K
YoY Change -15.15% 0.0%
% of Gross Profit
Operating Expenses $5.129M $10.62M
YoY Change -51.69% 16.34%
Operating Profit -$7.403M -$10.54M
YoY Change -29.77% 11.67%
Interest Expense $0.00 $30.00K
YoY Change -100.0% -88.46%
% of Operating Profit
Other Income/Expense, Net $10.00K $25.00K
YoY Change -60.0% -93.99%
Pretax Income -$7.390M -$10.52M
YoY Change -29.75% 16.63%
Income Tax
% Of Pretax Income
Net Earnings -$7.393M -$10.52M
YoY Change -29.7% 16.55%
Net Earnings / Revenue -1394.91% -335.12%
Basic Earnings Per Share -$0.34
Diluted Earnings Per Share -$949.9K -$0.34
COMMON SHARES
Basic Shares Outstanding 30.51B
Diluted Shares Outstanding 30.51B

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.30M $55.90M
YoY Change -61.9% -40.78%
Cash & Equivalents $22.60M $55.86M
Short-Term Investments $0.00
Other Short-Term Assets $2.600M $1.200M
YoY Change 116.67% -20.0%
Inventory
Prepaid Expenses
Receivables $0.00 $1.492M
Other Receivables $0.00 $0.00
Total Short-Term Assets $23.90M $58.60M
YoY Change -59.21% -39.66%
LONG-TERM ASSETS
Property, Plant & Equipment $5.900M $2.632M
YoY Change 124.16% -33.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $846.0K
YoY Change 53.66% 101.91%
Total Long-Term Assets $7.200M $10.71M
YoY Change -32.77% 90.84%
TOTAL ASSETS
Total Short-Term Assets $23.90M $58.60M
Total Long-Term Assets $7.200M $10.71M
Total Assets $31.10M $69.31M
YoY Change -55.13% -32.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $1.660M
YoY Change -63.86% -0.24%
Accrued Expenses $6.700M $6.400M
YoY Change 4.69% 236.84%
Deferred Revenue $15.18M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.300M $24.31M
YoY Change -65.85% -2.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.500M $5.200M
YoY Change -32.69% 333.33%
Total Long-Term Liabilities $3.500M $5.200M
YoY Change -32.69% 333.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.300M $24.31M
Total Long-Term Liabilities $3.500M $5.200M
Total Liabilities $11.80M $29.55M
YoY Change -60.07% 13.44%
SHAREHOLDERS EQUITY
Retained Earnings -$114.3M
YoY Change 55.92%
Common Stock $154.0M
YoY Change 2.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.24M $39.76M
YoY Change
Total Liabilities & Shareholders Equity $31.10M $69.31M
YoY Change -55.13% -32.53%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$7.393M -$10.52M
YoY Change -29.7% 16.55%
Depreciation, Depletion And Amortization $280.0K $330.0K
YoY Change -15.15% 0.0%
Cash From Operating Activities -$8.330M -$11.34M
YoY Change -26.54% 43.36%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $8.000M
YoY Change -100.0% -119.52%
Cash From Investing Activities $0.00 $8.000M
YoY Change -100.0% -119.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 100.0K
YoY Change -30.0% -99.86%
NET CHANGE
Cash From Operating Activities -8.330M -11.34M
Cash From Investing Activities 0.000 8.000M
Cash From Financing Activities 70.00K 100.0K
Net Change In Cash -8.260M -3.240M
YoY Change 154.94% -115.41%
FREE CASH FLOW
Cash From Operating Activities -$8.330M -$11.34M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$8.330M -$11.34M
YoY Change -26.54% 50.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10541000
CY2020Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5129000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10617000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2802000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
13679000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7403000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
25000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
57000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-427000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
427000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2551000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7393000
us-gaap Net Income Loss
NetIncomeLoss
-22207000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7393000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10514000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13487000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22195000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
35000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
262000
CY2020Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
808000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
507000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
25702000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
870000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
60234000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
726000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11691000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
49290000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
97000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
39758000
us-gaap Profit Loss
ProfitLoss
-13487000
us-gaap Profit Loss
ProfitLoss
-22207000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
581000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
661000
us-gaap Share Based Compensation
ShareBasedCompensation
1639000
us-gaap Share Based Compensation
ShareBasedCompensation
1611000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-2000
umrx Noncash Consideration Received From Customer
NoncashConsiderationReceivedFromCustomer
808000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
55000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-176000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1440000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
503000
umrx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-718000
umrx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-673000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
141000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1504000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
558000
umrx Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-789000
umrx Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-718000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1003000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2774000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16217000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22862000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
22988000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22946000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
35000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
135000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16082000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38679000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. <font style="color:#000000;">The extent to which the COVID-19 pandemic may directly or indirectly impact its business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there is not a material impact to its condensed consolidated financial statements as of and for the three and six months ended June&#160;30, 2020; however, actual results could differ from those estimates and there may be changes to its estimates in future periods.</font></p>
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2020Q1 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
43
CY2019 umrx Deficiency Letter From Listing Qualifications Department Notifying Period
DeficiencyLetterFromListingQualificationsDepartmentNotifyingPeriod
P30D
CY2019Q4 umrx Minimum Bid Price Of Common Stock
MinimumBidPriceOfCommonStock
1.00
CY2019 umrx Initial Period To Regain Compliance With Minimum Bid Price Rule
InitialPeriodToRegainComplianceWithMinimumBidPriceRule
P180D
CY2019 umrx Additional Period To Regain Compliance With Minimum Bid Price Rule
AdditionalPeriodToRegainComplianceWithMinimumBidPriceRule
P180D
CY2020Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
487000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
485000
CY2020Q2 umrx Fair Value Assets Transfers Involving Level Three
FairValueAssetsTransfersInvolvingLevelThree
0
CY2020Q2 umrx Fair Value Liabilities Transfers Involving Level Three
FairValueLiabilitiesTransfersInvolvingLevelThree
0
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1033000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2500000
CY2020Q2 umrx Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3806000
CY2019Q4 umrx Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2987000
CY2020Q2 umrx Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
133000
CY2019Q4 umrx Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
750000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
655000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
894000
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5627000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7131000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
870000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
885000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1639000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1611000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3477709
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4685428
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2020Q2 us-gaap Severance Costs1
SeveranceCosts1
100000
us-gaap Severance Costs1
SeveranceCosts1
1800000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1818000
us-gaap Restructuring Charges
RestructuringCharges
1843000
CY2020Q2 us-gaap Restructuring Reserve
RestructuringReserve
25000

Files In Submission

Name View Source Status
0001564590-20-039357-index-headers.html Edgar Link pending
0001564590-20-039357-index.html Edgar Link pending
0001564590-20-039357.txt Edgar Link pending
0001564590-20-039357-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
umrx-10q_20200630.htm Edgar Link pending
umrx-20200630.xml Edgar Link completed
umrx-20200630.xsd Edgar Link pending
umrx-20200630_cal.xml Edgar Link unprocessable
umrx-20200630_def.xml Edgar Link unprocessable
umrx-20200630_lab.xml Edgar Link unprocessable
umrx-20200630_pre.xml Edgar Link unprocessable
umrx-ex311_33.htm Edgar Link pending
umrx-ex312_32.htm Edgar Link pending
umrx-ex321_31.htm Edgar Link pending
umrx-ex322_30.htm Edgar Link pending